Introduction
High-dose therapy followed by auto-SCT is an integral component of the management of plasma cell disorders, such as multiple myeloma (MM) and light chain amyloidosis (AL). [1] [2] [3] [4] [5] In fact, MM remains the most common indication for auto-SCT in North America. Auto-SCT can also provide a potentially curative option for some patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease. [6] [7] [8] [9] PBSCs are the preferred graft type for auto-SCT, given the faster engraftment and potential for less contamination of infused cells with tumor cells compared with BM. PBSCs are typically mobilized using G-CSF alone or in combination with chemotherapy. Peripheral blood CD34 (PB-CD34) counts have been shown to correlate with PB-CD34 apheresis collections and have been used to trigger when apheresis should commence. The success of mobilization is influenced by several factors such as previous therapy, mobilization strategy and underlying disease. [10] [11] [12] [13] [14] [15] [16] Patients who fail to mobilize often have G-CSF dose escalation and, if unsuccessful, mobilization is reattempted with chemotherapy and G-CSF. More recently, plerixafor (AMD3100), a novel mobilizing agent, has been found to enhance G-CSFbased collection in patients with NHL and MM, raising the possibility of early intervention in poor mobilizers. 17, 18 Although the relationship between circulating CD34 counts and eventual CD34 yield is well known, it is not clear whether the PB-CD34 threshold for initiating apheresis should be tailored to the collection goal in order to avoid failed attempts at stem cell collection.
Patients and methods
We identified 910 patients with plasma cell disorders from our prospectively maintained database, who had a first attempt at G-CSF-based PBSC mobilization, including MM (565; 62%) or AL (345; 38%), and 656 first-time G-CSF-based PBSC mobilizers with NHL (562; 86%) or Hodgkin's disease (94; 14%) seen between January 2000 and September 2008. Salvage attempts were excluded, as were first attempts using CY þ G-CSF, plerixafor þ G-CSF or G-CSF þ GM-CSF combinations. All patients provided written informed consent for use of their medical records. Approval from the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
Stem cells are usually collected using G-CSF priming, with CY and G-CSF typically used for remobilization in patients who failed the initial attempt or in patients with myeloma with high tumor burden. Patients who had chemotherapy-primed mobilization are not included in the current analysis. G-CSF was administered s.c. (10 mg/ kg) daily until the completion of stem cell collection, with apheresis beginning on the fifth day after starting G-CSF, provided an adequate PB-CD34 count was reached. Our current practice is to obtain a PB-CD34 count on day 4 of G-CSF, with days counted from the first day of G-CSF as day 1. If the PB-CD34 count is X10/mL, patients will initiate collection the next day (day 5); otherwise it is rechecked on day 5 and apheresis is initiated the next day if they reach the threshold. The number of days of apheresis and the time at which collection can be be stopped were based on either achievement of the predetermined PBSC collection goal or at the discretion of the primary transplant physician in patients who were not collecting well. Patients who fail to achieve the threshold PB-CD34 count by day 5 typically had their G-CSF increased to 16 mcg/kg twice daily as per current practice.
PBSC collections were performed using either the CaridianBCT COBE Spectra (CaridianBCT, Lakewood, USA) or the Fenwal Amicus (Fenwal, Lake Zurich IL, USA). The Fenwal Amicus was the preferred device for PBSC collection during the period examined, with the COBE Spectra used for patients sensitive to fluid volume (for example, amyloid patients), patients with high platelet counts and when a Fenwal Amicus device was not available. All PBSC collections had an end point of 5 h processing time. If the patient's preprocedure peripheral WBC count was 435 Â 10 9 /L, the maximum blood flow rate was 65 mL/min. This was determined, as previous studies had demonstrated an adverse effect of high WBC on CD34 þ cell yields. [19] [20] [21] If the patient's preprocedure WBC count was o35 Â 10 9 /L, maximum blood flow varied according to the apheresis device, details of which are given below. Anticoagulant (AC) was ACD-A (Baxter Healthcare, Deerfield, IL, USA), ACD-A and heparin, or a mixture of ACD-A, normal saline and heparin. If a patient could not receive heparin, the AC was ACD-A, AC ratio was 12:1, and the maximum blood flow rate was determined by the instrument according to patient blood volume, on both instruments.
Several Fenwal Amicus apheresis systems (version 2.51) were used. If the patient's preprocedure peripheral WBC count was o35 Â 10 9 /L, the cycle volume was 1400 mL, maximum blood flow rate was 90 mL/min, citrate infusion rate was 2.50 mg/kg/min and the AC ratio was 13:1. If the patient's preprocedure peripheral WBC count was 435 Â 10 9 /L, the cycle volume was 1000 mL, citrate infusion rate was 1.25 mg/kg/min and the AC ratio was 12:1. The plasma flush setting was 8 mL, the MNC and RBC offset settings were 1.5 and 5.0, respectively, for most of the collections. During the period March 2005-September 2007 (141 patients), variable MNC (0.0-2.3) and RBC (6.0-9.0) offsets were used to maximize CD34 þ cell and lymphocyte content of the product while minimizing granulocyte and platelet content during studies conducted at our institution. 22 Several COBE Spectra apheresis instruments (version 7) were used. A manual technique with an HCT reading of 1% and collection rate of 1 mL/min was used. If the patient's preprocedure peripheral WBC count was p35 Â 10 9 /L, the maximum blood flow rate was 100 mL/ min, the AC infusion rate was 1.0 mL/min per L of total blood volume and the AC ratio was 26:1. If the patient's preprocedure peripheral WBC count was 435 Â 10 9 /L, the maximum blood flow rate was 65 mL/min, the AC infusion rate was 1.0 mL/min per L of total blood volume and the AC ratio was 12:1.
Sensitivity and specificity analysis was used to define the ideal cutoff points for PB-CD34 counts to predict predefined outcomes. In this current analysis, we used a CD34 yield of 2 million CD34 cells/kg as the minimum cell dose required to perform a single auto-SCT, and 4 million CD34 cells/kg as the ideal collection required for a single transplant for MM or lymphoma. The w 2 and Fisher's exact tests were used to compare differences between nominal variables and the Mann-Whitney U-test or Kruskal-Wallis test were used for continuous variables.
Results

Plasma cell disorders
A total of 910 patients with MM or amyloidosis underwent first attempt at stem cell mobilization and were included in the current analysis. Of these, 860 patients (94.5%) proceeded to at least one attempt at apheresis, either having met the threshold criteria for PB-CD34 count or at physician's discretion. Patients underwent a median of three apheresis sessions (range; 1-12). Among these, 532 (62%) had three sessions or less and 774 (90%) had five or less. The median (range) CD34 cell collection (millions/kg) was 7.96 (0.1-29.7) and the median (range) average daily CD34 cell collection (millions/kg) was 2.35 (0.1-29.7).
We first determined the best day-4 PB-CD34 cutoff as a predictor for collecting at least 2 million CD34 cells/kg and it was found to be 9.2/mL. A total of 673 patients (74%) had a PB-CD34 count of X9.2/mL on day 4. Among those with X9.2/mL, only 1.6% failed to collect at least 2 million, compared with 27% who had a PB-CD34 o9.2 (Po0.001). The median (range) PB-CD34 count on day 4 among those failing to collect at least 2 million CD34 cells/kg was 4 (0-54), compared with 19.4 (0-357) among those who succeeded (Po0.001; Figure 1a) .
Patients who did not reach the threshold of 10/mL by day 4 had a repeat testing on day 5. In all, 48% of the 257 patients who failed to reach a PB-CD34 count of 10/mL by day 4 achieved this threshold by day 5. The best day-4 PB-CD34 cutoff predicting the probability of achieving the threshold by day 5 was 6/mL, with 89% of patients over 6/mL reaching a day-5 PB-CD34 count of 10/mL compared with 35% of the remaining; Po0.001). The best cutoff for PB-CD34 by day 5 for predicting a collection of at least 2 million CD34 cells/kg was 11/mL. If the patient reached a PB-CD34 count of 11/mL by day 4 or 5 (n ¼ 740; 82%), the probability of failing to collect the minimum of 2 million CD34 cells/kg was 2% vs 35%, if it was o11/mL (Po0.001). The median (range) PB-CD34 count on day 4 day 5 (whichever was higher) among those failing to collect at least 2 million CD34 cells/kg was 6 (0-54), compared with 21 (0-357) among those who succeeded (Po0.001; Figure 1b ). The actuarial probability of reaching the minimum goal by days of apheresis depending on whether the goal was reached by day 4 (group 1) or day 5 (group 2) or not reached (group 3) is shown in Figure 2 .
We then determined cutoffs based on ideal targets using only those patients achieving a PB-CD34 count of 410/mL by day 4 or 5, as these patients would have started collection without any change in the mobilization technique such as doubling the dose of growth factor. We considered a maximum of five collections to achieve the goal as being ideal, taking into account the most commonly used/desired practice of collecting during weekdays. We used stem cell collections of 4 million CD34 cells/kg, 8 million CD34 cells/kg and 12 million CD34 cells/kg as ideal goals for single, two or three transplants, respectively, as had been our practice during this study period. Among those with a day-4 or day-5 PB-CD34 count of 410/mL, 87% yielded 4 million cells/kg within five collections or less. The best day-4 or day-5 PB-CD34 count predicting 4 million cells/kg yield within five collections or less was 17/mL (Po0.001). Similarly, the best day-4 or day-5 PB-CD34 count predicting 8 million CD34 cells/kg yield within five collections or less was 21/mL and a 12 million CD34 cells/ kg yield was 28/mL. Among those with day-4 or -5 PB-CD34 count of X21/mL, 89% yielded 8 million cells/kg compared with 49% among those with a PB-CD34 count of o21/mL (Po0.001). Similarly, among those with day-4 or -5 PB-CD34 count of X28/mL, 79% reached 12 million in o5 days compared with 17% among those with a PB-CD34 count of o28/mL (Po0.001).
Finally, we examined whether poor collection on the first day, despite a PB-CD34 count of 410, predicts for poor overall yield. Day 1 collection (million/kg) of o0.8 million CD34 cells/kg best predicted failure to reach an eventual target of 2 million CD34 cells/kg, with 38% below the cutoff failing to reach the goal compared with 2% for those above the cutoff (Po0.001).
Lymphoma
A total of 656 patients with lymphoma underwent a first attempt at stem cell mobilization and were included in the current analysis. Of these, 565 patients (86%) proceeded to at least one attempt at apheresis, either having met the threshold criteria for PB-CD34 count or at physician's discretion. Patients underwent a median of three apheresis sessions (range; 1-8). Among these, 394 (70%) had three sessions or less and 533 (94%) had five or less .The median (range) CD34 collection (millions/kg) was 4.65 (0.1-26.8) and the median (range) average daily CD34 collection (millions/kg) was 1.47 (0.1-26.8). Predicting outcome in stem cell mobilization S Sinha et al As with the previous cohort, we first determined the best day-4 PB-CD34 cutoff for being able to collect at least 2 million CD34 cells/kg to be 9/mL. A total of 383 patients (58%) had a PB-CD34 count of X9/mL on day 4. Among those with X9/mL, only 7% failed to yield at least 2 million CD34 cells compared with 55% who had a PB-CD34 count o9 (Po0.001). The median (range) PB-CD34 count on day 4 among those failing to yield at least 2 million CD34 cells/ kg was 4.4 (0-33) compared with 15 (0-140) among those who succeeded (Po0.001; Figure 3a) .
We then examined the proportion of patients achieving the threshold PB-CD34 of 10/mL by day 5 and found that 37% of the 305 patients who failed to reach a PB-CD34 count of 10/mL by day 4 did so by day 5. Similar to myeloma/amyloid cohorts, the best cutoff predicting the probability of achieving the target by day 5 was a PB-CD34 count of 6/mL on day 4, with 74% of patients with a day-4 PB-CD34 count of X6/mL reaching the threshold on day 5 compared with 19% of the rest (Po0.001). The median (range) PB-CD34 count on day 4 or day 5 (whichever is higher) among those failing to collect at least 2 million CD34 cells/kg was 6.3 (0-34) compared with 17 (0-140) among those who succeeded (Po0.001; Figure 3b ). The actuarial probability of reaching the minimum goal by days of apheresis depending on whether the goal was reached by day 4 (group 1) or day 5 (group 2) or not reached (group 3) is shown in Figure 4 .
We then determined cutoffs based on ideal targets (4 million CD34 cells/kg) using only those patients achieving a PB-CD34 count of 410/mL by day 4 or 5. Here too we used a maximum of five collections to achieve the ideal goal, considering the usual practice of collection during weekdays. The best day-4 or day-5 PB-CD34 count predicting 4 million cells/kg yield in five collections was 15/mL. Among those with day-4 or -5 PB-CD34 count of X15/mL, 2% failed to reach 4 million in o5 days compared with 21% among the rest (Po0.001).
Finally, we examined whether poor collection on the first day, despite a PB-CD34 count of 410 predicts for poor overall yield. Day 1 collection (million/kg) of o1.1 million CD34 cells/kg best predicted failure to obtain an eventual yield of 2 million CD34 cells/kg, with 38% below the cutoff failing to reach the goal compared with 1% of those above the cutoff (Po0.001).
Discussion
Approximately 10-30% of patients with MM or lymphoma fail to yield the minimum number of CD34 þ cells (2 millions/kg) to undergo a single cycle of auto-SCT. [23] [24] [25] [26] This collection failure results in increased resource utilization in terms of marked increase in use of growth factors, mobilization reattempts using chemotherapy, hospitalizations, need for transfusions and antibiotics for neutropenic fever. Although the use of chemotherapy allows better stem cell collection, it lengthens the collection process, delays the platelet engraftment and is associated with increased risk of febrile neutropenia and other infections complications. 26 One of the recent advances in this field has been the introduction of plerixafor (AMD3100), a CXCR4 inhibitor. Interaction of chemokine stromal cell-derived factor 1 and CXCR4 receptor is an important component of the Figure 4 The figure shows the actuarial probability of reaching the 2 million CD34 cells/kg by days of apheresis depending on whether the goal (10/mL) was reached by day 4 (group 1) or day 5 (group 2) or not reached (group 3) (Po0.001) in patients with lymphoma.
Predicting outcome in stem cell mobilization S Sinha et al mechanism of retention of stem cells in the BM. 27, 28 It has been proposed that plerixafor mobilizes CD34 cells by inhibition of the SDF-1/CXCR4 interaction responsible for stem cell homing and retention. 29, 30 Plerixafor administered in combination with G-CSF has been shown in phase I and phase II studies to significantly increase the number of PB-CD34 cells by a median of fivefold, as well as CD34 cell collection. 30, 31 In a phase II crossover study of patients with MM and lymphoma, plerixafor was well tolerated and administration of plerixafor increased the likelihood of obtaining X5 Â 10 6 CD34 cells/kg and allowed collection of this cell dose in fewer apheresis days compared with G-CSF alone. 31 Results from a phase III study in patients with non-Hodgkin's lymphoma demonstrated statistically significant superiority of plerixafor in combination with G-CSF in achieving minimal and optimal collections compared with placebo and G-CSF. 18 However, routine use of the drug for stem cell collection is limited by the high cost, and the exact patient population in which a pharmacoeconomic benefit can be obtained by its routine use has not been defined.
Another approach would be to use the drug selectively in patients with a high likelihood of collection failure or with a need for prolonged collection with multiple apheresis sessions. However, predicting the likelihood of failure on the basis of PB-CD34 counts or initial collections has not been well studied, in particular among patients planning to provide for more than one transplant. Here, we retrospectively studied a large cohort of patients with MM and lymphoma from our transplant database to define parameters for early identification of patients likely to fail mobilization, who are hence candidates for early intervention. First of all, our study supports the cutoff point of PB-CD34 as X10/mL to begin mobilization, the guidelines that we follow currently in our clinical practice. Among the myeloma/amyloidosis cohort, 72% reached the traditional cutoff of 10/mL on day 4, of whom only 1.7% failed to collect at least 2 million CD34 cells/kg compared with 25% among the rest. Nearly half of the patients who failed to reach a PB-CD34 count of 10/mL by day 4 achieved the number by day 5, and a significant proportion of these patients reached the minimum goal. Taken together, an ability to achieve the threshold of 10/mL at least by day 5 translated into a 97% probability of collecting the minimum number of required cells. However, 40% of those who had counts o10/mL eventually failed to collect the minimum, despite the standard practice of increasing the growth factor dose, highlighting the need for alternate approaches. It seems reasonable to use the day-4 or day-5 PB-CD34 count, as a substantial proportion of patients will achieve the threshold value by day 5 and will have a similar outcome as those reaching the threshold by day 4. However, these patients collect slower than patients who reache the threshold on the first day of testing, possibly adding extra days of collection. This once again highlights the need for careful pharmacoeconomic analyses before routine adoption of treatment algorithms using plerixafor. Although intervention based on these parameters may prevent failure to collect the minimum number of cells, most would prefer to have 4-5 million CD34 cells/kg cells to reduce the risk of slow or incomplete engraftment. The existing data do not allow exploration of numbers beyond that targeted in routine clinical practice for all patients. However, we have been able to show that higher threshold numbers of PB-CD34 cells have to be targeted to achieve the increased goals within an ideal number of apheresis procedures. Other studies have explored alternative approaches to enhancing the stem cell collection yield. Cottler-Fox et al. developed a formula that will allow determination of the blood volume to be processed during apheresis on the basis of the number of CD34 cells desired, the PB-CD34 counts, machine collection efficiency and patient weight. 32 This represents another variable that can be modified on the basis of PB-CD34 counts, thus allowing for an efficient stem cell collection process.
In conclusion, this study provides valuable information to guide the development of clinically relevant algorithms for cost-effective use of newly available drugs such as plerixafor. Given that the majority of patients reach the threshold of 10/mL by day 5 and owing to the high rate of success among patients achieving this threshold, we recommend consideration of plerixafor for patients who fail to reach a PB-CD34 count of 6/mL by day 4 or 10/mL by day 5 after starting GCSF. When collection for more than one transplant is planned, a higher cutoff commensurate with the intended collection should be used as a trigger for addition of plerixafor. Finally, we recommend initiation of plerixafor in patients who achieve the threshold for PB-CD34 count, but fail to collect at least 1 million CD34 cells/kg on the first day of collection. Given our current observations, we have already implemented algorithms that are being validated. 33 The data confirm the use of current guidelines for PB-CD34 cells counts for initiating apheresis, thus minimizing the risk of complete failure. However, the study highlights the need to use higher PB-CD34 thresholds that are adapted to the targeted collection goal for the particular clinical situation. Finally, identification of poor yielders after the start of collection potentially provides another time point for early intervention, which needs to be prospectively studied.
